Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Study Overview
=================
Brief Summary
-----------------
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs).

Official Title
-----------------
An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Conditions
-----------------
Refractory Partial Onset Seizures

Intervention / Treatment
-----------------
* Drug: Rufinamide


Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Completion of Study E2080-A001-301 and full compliance with the inclusion and exclusion criteria for that study (excluding criteria that are related to seizure occurrences). Patient willing to participate and written consent signed by patient or legal guardian provided prior to entering this study or undergoing any study procedures. In addition, if the patient is unable to provide written informed consent and it is provided by a legal guardian, assent of the patient (if the patient is able) must also be obtained. Female patients of non-childbearing potential by reason of surgery, radiation, or menopause (at least one year post onset); female patients of childbearing potential who are using at least two approved methods of contraception (such as an intrauterine device [IUD], implant, oral contraceptive, or barrier method plus spermicide). Use of a low-dose estrogen oral contraceptive alone will not be permitted. Female patients of childbearing potential must agree to continue to use two approved methods of contraception through the follow-up visit or for 30 days after their final dose of study medication, whichever is longer. EXCLUSION CRITERIA: Discontinuation from Study E2080-A001-301 for any reason, before the termination of the study. Evidence of non-compliance with study drug or ongoing AED dosing during Study E2080-A001-301. Evidence of clinically significant disease (cardiac, respiratory, gastrointestinal, hepatic (e.g., ALT > 3x ULN), hematologic, renal, or psychiatric disease, etc.) that in the opinion of the Investigator could affect the patient's safety or trial conduct. Progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors. History of alcohol abuse in the past 2 years. History of suicide attempt within the previous 10 years. Multiple drug allergies (dematological, heatological or organ toxicity) or more than one severe drug reaction. Concomitant use of felbamate or vigabatrin. Pregnancy. Clinically significant ECG abnormality. All patients with a diagnosis of Congenital Short QT Syndrome. Patients with a family history of Congenital Short QT Syndrome may be excluded on the basis of the Investigator's clinical judgement. Presence of major active psychiatric disorder. Patients will be allowed who are taking a stable dose of selective serotonin reuptake inhibitor (SSRI) or mixed serotonin and norepinephrine uptake inhibitor antidepressant.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rufinamide (Rufinamide During Core Study)<br> | Drug: Rufinamide<br>* Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).<br>* Other names: E2080;|
| Experimental: Rufinamide (Placebo During Core Study)<br> | Drug: Rufinamide<br>* Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).<br>* Other names: E2080;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase | Seizure data was collected via patient diaries. OL refers to open-label. | Baseline, Titration Phase (Days 1 to 18), Maintenance Phase | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Refractory Partial Onset Seizures, epilepsy